NASDAQ:INVO INVO Bioscience (INVO) Stock Price, News & Analysis $0.38 +0.00 (+0.05%) As of 02/21/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About INVO Bioscience Stock (NASDAQ:INVO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get INVO Bioscience alerts:Sign Up Key Stats Today's Range$0.37▼$0.4150-Day Range$0.35▼$0.9652-Week Range$0.63▼$3.50Volume146,006 shsAverage Volume1.59 million shsMarket Capitalization$1.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewINVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.Read More… Receive INVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address INVO Stock News HeadlinesNAYA Biosciences To Raise $9.5 Mln Through Public Offering Of UnitsJanuary 13, 2025 | markets.businessinsider.comNAYA Biosciences to present insights into mode of action of NY-303November 1, 2024 | markets.businessinsider.comShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recent DOGE moves… What Elon Musk is about to do next could not only shock the world… But also put an extra $30,000 a year in your pocket.February 22, 2025 | Brownstone Research (Ad)NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular CarcinomaOctober 24, 2024 | globenewswire.comNAYA Biosciences Inc (INVO)October 24, 2024 | investing.comINVO Bioscience confirms name change, new trading symbol following NAYA mergerOctober 22, 2024 | markets.businessinsider.comINVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA BiosciencesOctober 21, 2024 | globenewswire.comUnited States shares higher at close of trade; Dow Jones Industrial Average up 0.47%October 14, 2024 | msn.comSee More Headlines INVO Stock Analysis - Frequently Asked Questions How have INVO shares performed this year? INVO Bioscience's stock was trading at $0.81 at the beginning of 2025. Since then, INVO shares have decreased by 53.1% and is now trading at $0.38. View the best growth stocks for 2025 here. How were INVO Bioscience's earnings last quarter? INVO Bioscience, Inc. (NASDAQ:INVO) announced its earnings results on Monday, November, 15th. The company reported ($4.80) earnings per share for the quarter, missing analysts' consensus estimates of ($4.00) by $0.80. The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.25 million. When did INVO Bioscience's stock split? INVO Bioscience shares reverse split on the morning of Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are INVO Bioscience's major shareholders? Top institutional shareholders of INVO Bioscience include Concourse Financial Group Securities Inc.. Insiders that own company stock include Andrea Goren, Steve Shum, Michael Jos Campbell and Matthew K Szot. View institutional ownership trends. How do I buy shares of INVO Bioscience? Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of INVO Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that INVO Bioscience investors own include NVIDIA (NVDA), NIO (NIO), Tesla (TSLA), Meta Platforms (META), Nikola (NKLA), Broadcom (AVGO) and Bilibili (BILI). Company Calendar Last Earnings11/15/2021Today2/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:INVO CUSIPN/A CIK1417926 Webwww.invobioscience.com Phone(978) 878-9505FaxN/AEmployees25Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,030,000.00 Net Margins-122.79% Pretax Margin-122.32% Return on EquityN/A Return on Assets-36.94% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.27 Sales & Book Value Annual Sales$5.77 million Price / Sales0.25 Cash FlowN/A Price / Cash FlowN/A Book Value($2.06) per share Price / Book-0.18Miscellaneous Outstanding Shares3,809,000Free Float3,769,000Market Cap$1.45 million OptionableNo Data Beta1.43 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:INVO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWatch This Robotics Demo Before March 17thJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.